Yamanouchi Pharmaceutical Company Ltd.

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Jeol Ltd.

The Nisshin Oil Mills, Ltd.

Microbial Chemistry Research Foundation

Medical Biological Laboratories Co., Ltd.

Zaidan Hojin Biselbutsu Kagaku Kenkyu Kai (microbial Chemistry Research

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (microbial Chemistry Research

Shuichi Sakamoto

Sumio Umezawa

Tsutomu Tsuchiya

Hamao Umezawa

Tomio Takeuchi

Akihiro Tanaka

Yasuo Isomura

Masamichi Okada

Makoto Takeuchi

Tetsushi Abe

Shin-ichi Tsukamoto

Junya Ohmori

Kyoichi Maeno

Jun-ichi Shishikura

Masao Sasamata

Hiroshi Inami

Kazuyuki Hidaka

Itsuro Shimada

Atsuyuki Kohara

Hiroyuki Inoue

Masaaki Hirano

Naoki Kato

Takashi Kamikubo

Kunihiro Niigata

Kenji Negoro

Akira Seto

Kazuo Kubo

Hidenori Iwamoto

Hiroshige Homma

Norihisa Mori

Hirokazu Kubota

Satoshi Hayashibe

Shinya Fujita

Masahiro Iwata

Masafumi Kudou

Shigeru Honda

Tomoyuki Yasunaga

Manabu Kawada

Tetsuo Shitara

Hirotsune Itahana

Masaru Takakura

Kazuhito Tanabe

Kiyohiro Kitagawa

Mitsuo Fujii

Takuma Morita

Eiji Kojima

Masunori Kajikawa

Shunji Kageyama

Masahito Sugiura

Tetsuya Kimizuka

Hideki Kubota

Kazushige Ohno

Kousei Kawamuki

Kiyoshi Yahiro

Takuji Nozawa

Kazuhiro Nakato

Ichio Noda

Kazuo Koshiya

Sakiko Urano

Ken-ichi Kazuta

Fumikazu Wanibuchi

A scatter diagram display device includes a principal component analysis section that performs principal component analysis on intensity or concentration map data that represents each element, a priority level setting section that sets a priority level to each element based on the results of the principal component analysis performed by the principal component analysis section, and a display control section that performs a control process that arranges a plurality of scatter diagrams generated by combining each element based on the priority level that has been set to each element by the priority level setting section, and displays the plurality of scatter diagrams on a display section.

Scatter diagram display device and surface analyzer

An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.

Anti-CXADR antibody

Thiazolobenzoimidazole derivatives

A tricyclic pyrrole or pyrazole derivative represented by the following general formula (I), or a pharmaceutically acceptable salt thereof, which shows strong affinity and selectivity for the 5-HT,receptor and is useful for the treatment of central nervous system diseases such as sexual disorders, eating disorders, anxiety, depression and sleeping disorders.

Tricyclic pyrrole or pyrazole derivative

Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative

Imidazole-substituted quinoxalinedione derivatives

1,2,3,4-tetrahydroquinoxalinedione derivative

Serine derivative

N-(3-pyrrolidinyl) benzamide derivative

Fused pyrazine derivatives

Mycaminosyl tylonolide derivatives represented by the following general formula ##STR1## (wherein R.sup.1 denotes hydroxyl group, a lower alkanoyloxy group, benzoyloxy group, azido group, or amino group which may optionally be substituted with a lower alkyl or a lower alkanoyl radical; R.sup.2 stands for hydrogen atom or hydroxyl group; R.sup.3 expresses hydrogen atom or formyl group; and means a double bond or a radical represented by ##STR2## and salts thereof.

Mycaminosyl tylonolide derivatives

3-Deoxy mycaminosyl tylonolide derivatives represented by the following general formula and salts thereof: ##STR1## wherein X represents an oxygen atom or .dbd.N--OR.sup.4 (wherein R.sup.4 represents hydrogen or lower alkyl); R.sup.1 represents a hydrogen atom, an acyl group or an alkylsilyl group; R.sup.2 represents a hydrogen atom or an acyl group; and R.sup.3 represents a hydrogen atom or a hydroxyl group. The compounds of this invention of the formula (I) are novel compounds and have excellent antibacterial activity.

3-deoxy mycaminosyl tylonolide derivatives

(Cycloalkylamino)methylenebis(phosphonic acid) represented by the general formula: ##STR1## in which, R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent a hydrogen atom or a lower alkyl group, and n represents an integer from 3 to 10, a lower alkyl ester thereof or a pharmaceutically acceptable salt thereof; and a bone-resorption inhibitor and an anti-arthritis containing the same.

(Cycloalkylamino)methylenebis(phosphonic acid) and medicines contaiing

'Novel bisphosphonic acid derivatives, and a bone resorption-inhibitor and an anti-arthritis containing a bisphosphonic acid derivative represented by the formula (I): ##STR1## wherein R.sup.2 represents a hydrogen atom, an alkyl group, etc.,

Bisphophonic acid derivatives and pharmaceutical compositions containing

(Cycloalkylamino)methylenebis(phosphonic acid)

Growing community of inventors

Tokyo, Japan

Shuichi Sakamoto